Ipsen SA Reports Q1 2025 Sales Growth
Ipsen SA, a French pharmaceutical company, has reported sales growth in the first quarter of 2025. The company’s sales growth was driven by all three therapeutic areas and an increasing contribution from its products Iqirvo and Bylvay.
Key Highlights
- Sales growth of 11.6% at constant exchange rates
- Strong performance across all three therapeutic areas
- Increasing contribution from products Iqirvo and Bylvay
Regulatory Update
Ipsen has submitted its regulatory application for Tovorafenib to the European Medicines Agency for pediatric low-grade glioma treatment.
Full-Year Guidance
The company has confirmed its full-year guidance, with total sales growth of 11.6% at constant exchange rates.
Future Outlook
Ipsen’s financial performance is expected to continue positively, driven by a strong pipeline and upcoming launches.